COMPANY

Alveus Therapeutics

HQ: Philadelphia, PA source · alveustx.com ↗

Keywords: metabolic ALV-100

Location: Philadelphia, PA · source · Jan 14, 2026

Profile checked Oct 10, 2026

Raises and deals from press releases

Raise Series A · $197M · announced Feb 24, 2026 Company release ↗
Source quote
- Feb 24, 2026 · Company release ↗
  “Alveus Therapeutics Announces Second and Final Closing of Oversubscribed Series A, Bringing Total Financing to $197 Million to Advance Next‑Generation Therapies for Obesity and Metabolic Diseases”

Raises announced in these releases: $197M disclosed.

From the company’s own releases; this list is partial. All raises and deals

Aug 10, 2026 Trial start Phase 2: Study to Assess the Effect and Safety of ALV-100 on Maintenance of Weight Loss source ↗
Feb 24, 2026 Raise Private equity round — Series A: $197M (total, as published), announced Feb 24, 2026. Source: company's own press page. source ↗
Feb 24, 2026 Raise Series A · $197M source ↗
Jan 8, 2026 Raise Private equity round — Series A: $160M (total, as published), announced Jan 8, 2026. Source: company's own press page. source ↗ · Form D filed Jan 14, 2026 SEC Form D ↗
Dec 29, 2025 Trial start Phase 1: Study of ALV-100 to Assess Safety, Tolerability, and PK/PD in Overweight/Obese Participants With or Without T2D source ↗

2027-04 (ESTIMATED) · Phase 1 · Study of ALV-100 to Assess Safety, Tolerability, and PK/PD in Overweight/Obese Participants With or Without T2D · NCT07399678
Aug 24, 2027 (ESTIMATED) · Phase 2 · Study to Assess the Effect and Safety of ALV-100 on Maintenance of Weight Loss · NCT07837973

Estimated primary completion per ClinicalTrials.gov. Dates move.

Raised: $357.0M. Last 2 years.

Feb 24, 2026 Private equity round — Series A: $197M (total, as published), announced Feb 24, 2026. Source: company's own press page. source ↗
Jan 8, 2026 Private equity round — Series A: $160M (total, as published), announced Jan 8, 2026. Source: company's own press page. source ↗ · Form D filed Jan 14, 2026 SEC Form D ↗

Record	Title	Phase	Status	Start	Primary completion
NCT07837973	Study to Assess the Effect and Safety of ALV-100 on Maintenance of Weight Loss	Phase 2	Recruiting	Aug 10, 2026	Aug 24, 2027 (estimated)
NCT07399678	Study of ALV-100 to Assess Safety, Tolerability, and PK/PD in Overweight/Obese Participants With or Without T2D	Phase 1	Recruiting	Dec 29, 2025	2027-04 (estimated)